Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Randomized Experiments

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

Crossover Experiments

Crossover Experiments

Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.

Research square·2026

Same author

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Future oncology (London, England)·2026

Same author

Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study.

American journal of veterinary research·2025

Same author

Assessment of treatment effect heterogeneity for multiregional randomized clinical trials.

Statistics in biopharmaceutical research·2025

Same author

Design and analysis of individually randomized group-treatment trials with time to event outcomes.

Lifetime data analysis·2025

Same author

Low intensity focused ultrasound stimulation in stroke: A phase I safety & feasibility trial.

Brain stimulation·2025

Same journal

Correction.

Journal of biopharmaceutical statistics·2026

Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026

Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026

Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026

Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026

Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Between-arm comparisons in randomized Phase II trials.

Sin-Ho Jung¹, Stephen L George

¹Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27710, USA. sinho.jung@duke.edu

Journal of Biopharmaceutical Statistics

|April 23, 2009

Summary

This summary is machine-generated.

This study introduces new statistical methods for selecting superior experimental therapies in randomized Phase II trials. These methods improve accuracy in identifying effective treatments, reducing errors in small sample, multi-stage clinical trial designs.

More Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Related Experiment Videos

Last Updated: Jun 23, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Area of Science:

Clinical Trial Design
Biostatistics
Pharmaceutical Research

Background:

Phase II clinical trials often randomize patients to multiple experimental therapy arms to assess efficacy against historical controls.
Independent evaluation of each arm is standard, but selecting the best-performing arm(s) for Phase III trials presents statistical challenges.
Existing between-arm comparison methods can suffer from high false selection rates, especially with small efficacy differences or in multi-stage, small-sample designs.

Purpose of the Study:

To develop and propose novel statistical methods for comparing multiple experimental arms within randomized Phase II trials.
To address the limitations of current methods, particularly concerning type I error inflation and suitability for small sample, multi-stage designs.
To enhance the accuracy and reliability of selecting superior experimental therapies for advancement to Phase III trials.

Main Methods:

Development of new statistical approaches for between-arm comparisons in randomized Phase II trials.
Focus on methods that properly account for small sample sizes and the multi-stage nature of these trials.
Addressing the issue of inflated false selection (type I error) probabilities inherent in some existing comparison techniques.

Main Results:

The proposed methods aim to provide more accurate selection of efficacious experimental therapies.
Improved control over type I error rates when comparing arms with subtle differences in efficacy.
Enhanced statistical validity for selection procedures in the context of typical Phase II trial designs.

Conclusions:

The proposed between-arm comparison methods offer a more robust solution for selecting superior treatments in randomized Phase II trials.
These advancements are crucial for optimizing the transition of promising therapies from Phase II to Phase III studies.
The new methods enhance the statistical rigor and efficiency of early-phase oncology drug development.